Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Deferred Taxes (2021 - 2025)

Historic Deferred Taxes for Collegium Pharmaceutical (COLL) over the last 5 years, with Q3 2025 value amounting to -$12.1 million.

  • Collegium Pharmaceutical's Deferred Taxes fell 3892.13% to -$12.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$25.7 million, marking a year-over-year decrease of 5145.33%. This contributed to the annual value of -$26.8 million for FY2024, which is 114542.5% down from last year.
  • Collegium Pharmaceutical's Deferred Taxes amounted to -$12.1 million in Q3 2025, which was down 3892.13% from -$2.9 million recorded in Q2 2025.
  • Collegium Pharmaceutical's Deferred Taxes' 5-year high stood at $2.1 million during Q3 2022, with a 5-year trough of -$62.6 million in Q2 2021.
  • Its 5-year average for Deferred Taxes is -$7.3 million, with a median of -$3.1 million in 2022.
  • Its Deferred Taxes has fluctuated over the past 5 years, first soared by 65623.34% in 2022, then plummeted by 949130.43% in 2024.
  • Quarter analysis of 5 years shows Collegium Pharmaceutical's Deferred Taxes stood at -$15.0 million in 2021, then skyrocketed by 92.82% to -$1.1 million in 2022, then surged by 68.65% to -$338000.0 in 2023, then plummeted by 2904.73% to -$10.2 million in 2024, then dropped by 19.46% to -$12.1 million in 2025.
  • Its Deferred Taxes was -$12.1 million in Q3 2025, compared to -$2.9 million in Q2 2025 and -$539000.0 in Q1 2025.